Related Experiment Video
Updated: Jan 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease
Juan Pedro-Botet1, Jose López-Miranda2, Lina Badimón3
1Unitat de Lípids i Risc Vascular, Department of Medicine, Hospital del Mar, Universitat Autònoma de Barcelona, Passeig Marítim, 25-29, 08003, Barcelona, Spain. 86620@parcdesalutmar.cat.
Insights
Lipid-lowering therapies, including statins and non-statins, reduce cardiovascular events. While some trials show reduced overall mortality, only one demonstrated a significant decrease in all-cause mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease remains a leading cause of death globally.
- Lipid-lowering therapies are crucial for managing cardiovascular risk.
- Historically, mortality data have been underrepresented in major lipid trials.
Purpose of the Study:
- To review and contrast mortality findings from key lipid-lowering trials.
- To compare outcomes of statins versus placebo.
- To evaluate intensive vs. moderate-intensity statin therapy and non-statin interventions.
Main Methods:
- Narrative review of pooled data from randomized clinical trials.
- Analysis of trials including statins, ezetimibe, and PCSK9 inhibitors.
- Focus on cardiovascular events and overall/all-cause mortality.
Main Results:
- Early trials (4S, LIPID, HPS) showed reduced overall mortality.
- Intensified lipid lowering and non-statin therapies (ezetimibe, PCSK9 inhibitors) reduce cardiovascular events.
- Only the ODYSSEY OUTCOMES trial demonstrated a reduction in all-cause mortality.
Conclusions:
- While lipid lowering effectively reduces cardiovascular events, its impact on all-cause mortality varies.
- Further investigation into therapies affecting all-cause mortality is warranted.
- Trial design and patient populations influence observed mortality outcomes.
Abstract:
Pooled data from randomized clinical trials on lipid-lowering therapy have provided valuable information and clinical insights. Although cardiovascular disease is a common cause of death, mortality data have rarely been prominent in key lipid trials. The 4S, LIPID and HPS trials were the first to demonstrate a reduction in overall mortality. Lower- versus higher-intensity statin trials and non-statin lipid-lowering trials with ezetimibe and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors proved that additional lipid lowering significantly reduces the occurrence of cardiovascular events. However, only the ODYSSEY OUTCOMES trial showed a reduction in all-cause mortality. The aim of the present narrative review was to contrast these results with those of other key lipid trials: those assessing statins compared with placebo, those evaluating intensive- versus moderate-intensity lipid-lowering therapy and, finally, those investigating non-statin lipid-lowering therapies.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...